ATE210990T1 - Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt - Google Patents

Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Info

Publication number
ATE210990T1
ATE210990T1 AT98907023T AT98907023T ATE210990T1 AT E210990 T1 ATE210990 T1 AT E210990T1 AT 98907023 T AT98907023 T AT 98907023T AT 98907023 T AT98907023 T AT 98907023T AT E210990 T1 ATE210990 T1 AT E210990T1
Authority
AT
Austria
Prior art keywords
tumors
progression
stops
viral agent
therapeutic viral
Prior art date
Application number
AT98907023T
Other languages
English (en)
Inventor
Alexander Fred The Uni Markham
Bld University
David Mark The Univer Meredith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE210990T1 publication Critical patent/ATE210990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT98907023T 1997-02-27 1998-02-24 Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt ATE210990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704046.3A GB9704046D0 (en) 1997-02-27 1997-02-27 Arrestable therapeutic
PCT/GB1998/000559 WO1998037905A1 (en) 1997-02-27 1998-02-24 Arrestable therapeutic viral agent

Publications (1)

Publication Number Publication Date
ATE210990T1 true ATE210990T1 (de) 2002-01-15

Family

ID=10808384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907023T ATE210990T1 (de) 1997-02-27 1998-02-24 Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Country Status (11)

Country Link
EP (1) EP0979093B1 (de)
JP (1) JP2001513634A (de)
AT (1) ATE210990T1 (de)
AU (1) AU6301398A (de)
CA (1) CA2280690A1 (de)
DE (1) DE69803052T2 (de)
DK (1) DK0979093T3 (de)
ES (1) ES2170479T3 (de)
GB (1) GB9704046D0 (de)
PT (1) PT979093E (de)
WO (1) WO1998037905A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355B1 (de) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors

Also Published As

Publication number Publication date
PT979093E (pt) 2002-06-28
AU6301398A (en) 1998-09-18
DK0979093T3 (da) 2002-04-02
EP0979093A1 (de) 2000-02-16
CA2280690A1 (en) 1998-09-03
EP0979093B1 (de) 2001-12-19
DE69803052T2 (de) 2002-07-25
WO1998037905A1 (en) 1998-09-03
JP2001513634A (ja) 2001-09-04
ES2170479T3 (es) 2002-08-01
DE69803052D1 (de) 2002-01-31
GB9704046D0 (en) 1997-04-16

Similar Documents

Publication Publication Date Title
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
ATE371372T1 (de) Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
ATE324119T1 (de) Verwendung von saccharid-konjugaten
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ATE194608T1 (de) 5-substituierte derivate von mycophenolsäure
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
ATE232396T1 (de) Oxydiertes thymosin beta 4
BR0010702A (pt) Novas quinonas como terapias de doenças
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DE60019104D1 (de) Gentherapy von lungenkrankheiten
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE360062T1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee